Introduction {#s1}
============

Mutations in IDH1 and IDH2 are found in gliomas and in acute myeloid leukemia. All mutations are heterozygous and result in changes to one of two amino acids: arginine 132 in IDH1, or either arginine 172 or arginine 140 in IHD2. Wild-type IDH1 catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG). The arginine mutations abolish its normal activity and instead mutant IDH1 and IDH2 reduce α-KG to generate the oncometabolite 2-hydroxyglutarate (2-HG) ([@bib14]), which in turn affects the function of multiple α-KG dependent dioxygenases, including the TET family of 5-methylcytosine (5 mC) hydroxylases ([@bib7a]; [@bib9]). In their *Cancer Cell* 2011 paper, Xu and colleagues examined the effects of excess production of 2-HG on downstream processes that could affect cancer progression. They showed that 2-HG could act as a competitive inhibitor for α-KG-dependent DNA demethylases, specifically Tet2. Ectopic expression of the mutant forms of IDH1 and IDH2 inhibited histone demethylation and 5mC hydroxylation. Examination of glioma samples from patients also showed that mutations in IDH1 were associated with increased histone methylation and decreased 5-hydroxymethylcytosine (5hmC) levels ([@bib15]).

In Supplemental Figure 3I, Xu and colleagues demonstrated that transfection of U-87 MG cells with the mutant IDH1^R132H^ increased the amount of 2-HG in the cells, as compared to transfection with wild-type IDH1 ([@bib15]). This is evidence that mutant IDH1 changes the physiological levels of 2-HG, and is replicated in Protocol 1.

Xu and colleagues first showed that 2-HG can occupy the same binding pocket as α-KG in *Caenorhabditis elegans* KDM7A, indicating it acts as a competitive inhibitor of α-KG. Importantly, they also presented evidence that 2-HG may outcompete α-KG, since 2-HG levels affected many enzymatic functions normally dependent on α-KG. In Figure 3A, they treated U-87 MG cells with cell permeable versions of α-KG and 2-HG, and examined levels of histone methylation by Western Blot. Treatment with increasing amounts of 2-HG led to increases in H3K9me2 and H3K79me2, consistent with the idea that 2-HG inhibited histone demethylases. This effect was abolished by co-treatment with α-KG, confirming a competitive relationship between the two metabolites ([@bib15]). This experiment is replicated in Protocol 2. Xu and colleagues also examined the effect of 2-HG on the TET family of 5 mC hydroxylases using an in vitro system of purified TET2 and double-stranded oligos containing a 5mC restriction digestion site in Figure 8A. Adding increasing concentrations of 2-HG abolished the ability of TET2 to convert 5 mC to 5hmC ([@bib15]). This experiment will be replicated in Protocol 5.

In addition to demonstrating that the metabolite 2-HG can affect the activity of α-KG-dependent enzymes, Xu and colleagues showed that treatment with mutant forms of IDH1 and IDH2 resulted in similar outcomes. In Figure 3D, they transfected U-87 MG cells with IDH1^R132H^ and assessed levels of histone methylation by Western blot. Transfection with IDH1^R132H^ increased histone methylation, and treatment with α-KG abolished this increase in histone methylation, consistent with the idea that α-KG and 2-HG are competitive metabolites ([@bib15]). This experiment will be replicated in Protocol 3. In Figure 7B, they also examined TET activity in the presence of mutant IDH1. While 5hmC levels are normally undetectable in HEK293 cells, transfection with TET catalytic domain (CD)-expressing plasmids increased 5hmC levels to detectable amounts. Co-transfection of TET-CD and wild-type IDH1 or IDH2 increased levels of 5hmC, as expected, while co-transfection of TET-CD with mutant forms of IDH1 and IDH2 decreased 5hmC levels ([@bib15]). This experiment is replicated in Protocol 4.

The work of Xu and colleagues ([@bib15]), along with work from Figueroa and colleagues ([@bib5]) and Lu and colleagues ([@bib8]), has generated much interest in the role of altered metabolites in the changing methylation patterns seen in various types of cancer. Using a different cell line than Xu and colleagues, Lu and colleagues demonstrated that mutations in IDH2, similar to mutations in IDH1, also generated abnormal levels of 2-HG which correlated with increased global methylation levels ([@bib8]). Kernystsky and colleagues, Duncan and colleagues and Turcan and colleague have also shown that expression of exogenous mutated IDH genes in immortalized human cancer cell lines or in erythroid progenitor cells caused increased production of 2HG and increased levels of methylation ([@bib2]; [@bib13]; [@bib7]). Sasaki and colleagues extended these inquiries by generating conditional knock-in IDH1 mutant mice. These mice displayed elevated serum levels of 2HG and similar patterns of hypermethylation as observed in AML patients ([@bib11]). Akbay and colleagues generated IDH2 mutant mice and also observed an increase in global methylation in heart tissue. They also demonstrated that mice carrying IDH mutant xenograft tumors displayed higher serum levels of 2HG ([@bib1]). Recently, 2-HG production has also been associated with MYC activation in some breast cancers, which also displayed increased levels of methylation as compared to tumors with lower levels of 2-HG ([@bib12]).

Materials and methods {#s2}
=====================

Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (\*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (\#) indicates information provided by the replicating lab.

Protocol 1: Gas chromatography-mass spectrometry measurement of cellular α-KG and 2-HG concentrations in U87MG cells ectopically expressing mutant IDH1 {#s2-1}
-------------------------------------------------------------------------------------------------------------------------------------------------------

This protocol describes how to transfect cells with exogenous wild-type IDH1 or mutant IDH1^R132H^ and assess levels of α-KH and 2-HG by gas chromatography-mass spectrometry (GC-MS), as seen in Supplemental Figure 3I.

### Sampling {#s2-1-1}

This experiment will be repeated independently 5 times for a final power of at least 92%.○ See Power calculations for details.Each experiment consists of three cohorts:○ Cohort 1: U-87 MG cells transfected with vector alone.○ Cohort 1: U-87 MG cells transfected with wild-type IDH1.○ Cohort 1: U-87 MG cells transfected with mutant IDH1.Each cohort will be assessed via GC--MS for:■ α-KG levels.■ 2-HG levels.

### Materials and reagents {#s2-1-2}

ReagentTypeManufacturerCatalog \#CommentsU-87 MG cellsCellsATCCHTB-14N-methyl-N-\[tert-butyldimethylsilyl\] trifluoroacetamideChemicalSigma--Aldrich375934-10× 1 MAgilent 6890-5973 gas chromatograph-mass spectrometerInstrumentAgilent6890-5973HP-5MS columnMaterialAgilent19091S-433I60 mm tissue culture dishesMaterialCorning430166DMEM; high glucoseMediumSigma--AldrichD5671Original unspecifiedOpti-MEM Reduced Serum MediumMediumLife Technologies31985-062Original unspecifiedVector only plasmid (GFP)PlasmidProvided by the original authorsIDH1-IRES-GFP vectorPlasmidProvided by the original authorsIDH1^R132H^-IRES-GFP vectorPlasmidProvided by the original authorsFBSReagentSigma--AldrichF2442Original unspecifiedTrypsin-EDTA solution, 1×ReagentATCCATCC-30-2101Penicillin-streptomycin solutionReagentATCCATCC-30-2300*Trans*IT^®^-LT1 transfection reagentReagentMirus BioMIR 2300Replaces SunBio-EZ (SunBio)Methoxyamine hydrochlorideReagentSigma--Aldrich226904PyridineReagentSigma--Aldrich33,553GenElute Endotoxin-free Plasmid Maxiprep KitKitSigma--AldrichPLEX15-1KTα-KGChemicalSigma--Aldrich75892L-2-HGChemicalSigma--Aldrich907900.2 µm filter vialsMaterialRestek25893CentrivapEquipmentLaboncoAnti-GAPDH-HRPAntibodyAbcamab9385Mouse monoclonal IgG~1~ α IDH1AntibodyAbcamab117976The original catalog number was not specified

### Procedure {#s2-1-3}

#### Notes {#s2-1-3-1}

U-87 MG cells are maintained in DMEM supplemented with 10% FBS at 37°C/5% CO~2~.All cells will be sent for mycoplasma testing and STR profiling.Transform, grow up and maxiprep vector only (GFP), IDH1-IRES-GFP, and IDH1^R132H^-IRES-GFP plasmids using a Endo-free Maxiprep kit following manufacturer\'s instructions.a. Confirm plasmid identity by sequencing.Plate U-87 MG cells in 60 mm dishes.a. First, run an optimization to determine the growth rate of the cells and optimal number of cells per plate for transfection.24 hr after plating, transfect cells with plasmids using *Trans*IT-LT1 transfection reagent and Opti-MEM medium according to the manufacturer\'s protocol.a. Transfect 8 µg of DNA per construct using appropriate amount of transfection reagent.i. Vector only (GFP).ii. Wild-type IDH1 (IDH1-IRES-GFP).iii. Mutant IDH1 (IDH1^R132H^-IRES-GFP).b. Prepare two plates per cohort; one will be harvested for Western blot confirmation of protein expression (Step 4), the other will be used for metabolite analyses (Step 5).For Western blot[:]{.ul} 48 hr after transfection, confirm protein expression by Western blot.Note: perform each time cells are transfected.a. Run Western blot as outlined in Protocol 2 Steps 3 through 17 with the following modifications:i. Blots do not need to be stripped and re-probed.ii. Blots will be probed with:Anti-IDH1; diluted according to the manufacturer\'s recommendation.Anti-GAPDH-HRP; 1:5000.a. Loading control.For metabolite analysis: 24 hr after transfection, remove culture medium, wash cells with cold PBS and immediately add 10 ml of pre-chilled (−80°C) 80% (vol/vol) methanol. Harvest cells by scraping and lyophilize following the manufacturer\'s instructions.a. Samples will be lyophilized in a speedvac with no heating to keep samples frozen throughout. Immediately after drying remove samples from the speedvac for derivitization.Oximate lyophilized samples with 20 µl 20 mg/ml methoxyamine hydrochloride in pyridine at 30°C for 60 min.Derivatize samples for 30 min at 70°C in 80 μl pyridine and 20 μl N-methyl-N-\[tert-butyldimethylsilyl\] trifluoroacetamide.Filter samples using 0.2 µm filter vials (PTFE).Inject 3 µl of samples for gas chromatography-mass spectrometry analysis (GC--MS) into Agilent 6890-5973 GC--MS. Use a HP-5MS column (30 m 0.25 mm 0.25 μm) for analysis. Program GC oven temperature from 60°C to 180°C at 5°C/min and from 180°C to 260°C at 10°C/min. Set the flow rate of carrier gas at 1 ml/min. Operate the mass spectrometer in the electron impact (EI) mode at 70 eV.Calculate relative α-KG and 2-HG concentrations by normalizing α-KG (29.86 min) and 2-HG (30.10 min) peak areas to the average of L-threonine (29.58 min), L-serine (29.96 min) and L-phenylalanine (30.74 min) peak areas.Repeat independently four additional times.

### Deliverables {#s2-1-4}

Data to be collected:○ Chromatograms and sequence files confirming plasmid identity.○ Data generated determining growth optimization.○ Full image of Western blot showing protein expression and loading controls.○ Mass spectra readouts of all samples.○ Raw values of peak areas for α-KG (29.86 min), 2-HG (30.10 min), L-threonine (29.58 min), L-serine (29.96 min) and L-phenylalanine (30.74 min).○ Quantification of average of peak areas for L-threonine (29.58 min), L-serine (29.96 min) and L-phenylalanine (30.74 min).○ Quantification of relative α-KG and 2-HG concentrations by normalization to average peak areas for L-threonine (29.58 min), L-serine (29.96 min) and L-phenylalanine (30.74 min).○ Bar graphs of relative α-KG or 2-HG concentrations (in percent) for each cell line (as in Supplemental Figure 3I).

### Confirmatory analysis plan {#s2-1-5}

Statistical analysis of the replication data:○ Note: At the time of analysis we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ One-way MANOVA of α-KG and 2-HG levels in vector-transfected, IDH1-wildtype transfected, and IDH1^R132H^-transfected cells with the following Bonferroni corrected comparisons:■ α-KG levels planned comparisons:vector vs IDH1^WT^.vector vs IDH^R132H^.IDH1^WT^ vs IDH^R132H^.■ 2-HG levels planned comparisons:vector vs IDH1^WT^.vector vs IDH^R132H^.IDH1^WT^ vs IDH^R132H^.Meta-analysis of original and replication attempt effect sizes:○ Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-1-6}

Aspects of the Western blot protocol are provided by the replicating lab; complete details of the original protocol were unavailable.Since the cell density during transfection is unknown in the original paper, the replicating lab will optimize growth conditions and cell density for transfection.

### Provisions for quality control {#s2-1-7}

All data obtained from the experiment---raw data, data analysis, control data and quality control data---will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/kvshc/>).Sequence data confirming plasmid identity.Western blots confirming exogenous protein expression.STR profiling confirming cell line authenticity.Mycoplasma testing confirming lack of contamination.Growth characteristics of the cells will be optimized.

Protocol 2: Western blot to assess histone methylation in U-87 MG cells following treatment with oct-2-HG and/or oct-α-KG {#s2-2}
-------------------------------------------------------------------------------------------------------------------------

This protocol describes how to treat U-87 MG cells with cell permeable versions of 2-HG and α-KG and assess histone methylation via Western blot, as seen in Figure 3A and Supplemental Figure 3F.

### Sampling {#s2-2-1}

The experiment will be repeated independently 3 times for a final power of 84%.○ See Power calculations for details.Each experiment consists of four cohorts:○ Cohort 1: untreated U-87 MG cells.○ Cohort 2: U-87 MG cells treated with 10 mM racemic Oct-2-HG.○ Cohort 3: U-87 MG cells treated with 20 mM racemic Oct-2-HG.○ Cohort 4: U-87 MG cells treated with 20 mM racemic Oct-2-HG and 5 mM oct-α-KG.Each sample will be blotted for:■ H3K9me2.■ H3K79me2.■ H3.

### Materials and reagents {#s2-2-2}

ReagentTypeManufacturerCatalog \#CommentsMouse monoclonal anti-H3K9me2AntibodyAbcamAb1220The original catalog number was not specifiedMouse monoclonal anti -H3K79me2AntibodyAbcamAb3594The original catalog number was not specifiedMouse monoclonal anti -H3AntibodyAbcamab10799The original catalog number was not specifiedGoat Anti-Mouse IgG H&L (HRP)AntibodyAbcamab97023We will use this for all mouse primariesU-87 MG cellsCellsATCCHTB-1460 mm tissue culture dishesMaterialCorning430166DMEM; high glucoseMediumSigma--AldrichD5671Original unspecifiedFBSReagentSigma--AldrichF2442Original unspecifiedOct-α-KGReagentCayman Chemical119702S(L)-Oct-2-HGReagentTRCH942596Original synthesized in house2R(L)-Oct-2-HGReagentTRCH942595Protease inhibitor cocktail (mammalian)ReagentSigma--AldrichP8340-1MLOriginal not specifiedTruPAGE TEA-tricine SDS running buffer (20×)ReagentSigma--AldrichPCG3001-500 MLOriginal not specifiedTruPAGE LDS sample buffer (4×)ReagentSigma--AldrichPCG3009-10 MLOriginal not specifiedTruPAGE DTT sample reducer (10×)ReagentSigma--AldrichPCG3005-1MLOriginal not specifiedTruPAGE transfer buffer (20×)ReagentSigma--AldrichPCG3011-500 MLOriginal not specifiedPBS, without MgCl~2~ and CaCl~2~ReagentSigma--AldrichD8537Original not specifiedHybond ECL nitrocellulose membranes; 20 cm × 20 cmReagentGE Healthcare (Sigma--Aldrich)GERPN2020DOriginal not specifiedPonceau S solution; 0.1% (wt/vol) in 5% acetic acidReagentSigma--AldrichP7170Original not specifiedTris Buffered Saline (TBS); 10× solutionReagentSigma--AldrichT5912Original not specifiedBradford reagentReagentSigma--AldrichB6916Original not specifiedECL DualVue Western Blotting MarkersReagentGE Healthcare (Sigma--Aldrich)GERPN810Original not specifiedECL Prime Western blotting systemReagentGE Healthcare (Sigma--Aldrich)GERPN2232Original not specifiedImageQuantSoftwareMolecular DynamicsVersion 5.2Typhoon scannerEquipmentGE Healthcare

### Procedure {#s2-2-3}

#### Notes {#s2-2-3-1}

U-87 MG cells are maintained in DMEM supplemented with 10% FBS at 37°C/5% CO~2~.All cells will be sent for mycoplasma testing and STR profiling.Plate U-87 MG cells in 60 mm dishes.24 hr after plating, treat cells with 10 or 20 mM racemic Oct-2-HG or 5 mM Oct-α-KG or vehicle (DMSO) for 4--6 hr.a. To form racemic mixtures of Oct-2-HG, mix equal amounts of the L and R enantiomers.Wash cells once with cold PBS, then lyse cells in 0.5 mL of SDS loading buffer.a. 4× SDS-PAGE loading buffer: 50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1% B-ME, 12.5 mM EDTA, 0.02% bromophenol blue.b. ^\#^Measure protein concentration using a CBX assay.Heat lysates at 99°C for 10 min.Run equal amounts of protein per well on a 4--20% SDS-PAGE gel at 220V until ladder marker reaches the bottom of the gel.^\#^Equilibrate gel in transfer buffer for 15 min.^\#^Meanwhile, cut membrane and 4 pieces 3 MM filter paper to size of gel.a. Soak membrane in MeOH for a few seconds, then wash with H~2~O.b. Soak membrane, 3 MM filter paper and pads in transfer buffer.i. Transfer buffer: 38 mM glycine, 47 mM Tris, 11 mM SDS, 20% MeOH.^\#^Assemble transfer cassette:a. red pole (+) \< clear plate \< pad \< 2 × 3 MM filter paper \< membrane \< gel \< 2 × 3 MM filter paper \< pad \< black pole (−).^\#^Add stirring bar and ice box to transfer box and fill box with transfer buffer until cassette is submerged.a. Run at 100 V for 1 hr.^\#^Wash membrane in wash buffer for 2 × 5 min.a. Wash buffer: 1× PBS with 0.05% Tween-20 and 0.1% sodium azide.^\#^Incubate membrane in blocking buffer for 30 min.a. Blocking buffer: 3% non-fat milk in PBS.^\#^Incubate membrane with one of the following primary antibody in blocking buffer for 2 hr at RT or O/N at 4°C (use manufacturer\'s suggested dilution in blocking buffer).a. H3K9me2.b. H3K79me2.c. H3.i. See Step 17 to strip and re-probe the blot with subsequent antibodies.^\#^Wash 5 min 2× with wash buffer.^\#^Incubate membrane with secondary antibody for 90 min at RT (use manufacturer\'s suggested dilution in blocking buffer).a. HRP-conjugated Goat Anti-Mouse IgG H&L: 1: 2000.^\#^Wash 3 × 5 min in wash buffer.^\#^Detect HRP-conjugated secondary antibodies with chemiluminescent detection according to the manufacturer\'s protocol and image on the Typhoon scanner.Strip the blot in between probes:a. Wash the membrane with 100 ml stripping buffer (100 mM beta-mercaptoethanol, 1% SDS 25 mM glycine pH 2.0) for 30 min with agitation.b. Wash the stripped membrane twice with Western blotting wash buffer, 600 ml each wash, for 10 min with agitation.c. Go to the blocking step of the western blot protocol.d. Check that stripping was successful by repeating the detection step (without re-probing). Record image of the stripped gel. This will confirm the first antibody-HRP conjugate is removed and/or inactivated. If the stripping procedure is successful, wash the membrane with washing buffer and repeat the blocking-probing and detection steps for the second antibody.i. Note: if stripping is unsuccessful, individual blots will be performed.Quantify intensity of bands on western blots using ImageQuant 5.2. Normalize H3k9me2 and H3K79me2 values to total H3 protein level.Repeat independently 2 additional times.

### Deliverables {#s2-2-4}

Data to be collected:○ Full scans of western blots for H3K9me2, H3K79me2 and H3 including ladder.○ Raw values of intensity of western blot bands.○ Quantification of H3K9me2 or H3K79me2 values normalized to total protein level. Levels of H3K9me2 and H3K79me2 in vehicle treated cells are set to relative intensity = 1 and all other conditions are expressed as fold change relative to the values for vehicle treated cells.○ Quantification of average values and standard deviations for each condition for triplicate experiments.○ Bar graph of average ± standard deviation of H3K9me2 and H3K79me2 levels normalized to H3 for each condition. Fold change in intensity relative to vehicle treated cells is plotted on the y axis (as seen in Supp. Figure 3F).

### Confirmatory analysis plan {#s2-2-5}

Statistical analysis of the replication data:○ Note: At the time of analysis we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ One-way MANOVA of normalized H3K9me2 and H3K79me3 levels in U-87 MG cells untreated or treated with 10 mM Oct-2-HG, 20 mM Oct-2-HG, or 20 mM Oct-2-HG and 5 mM alpha-KG with the following Bonferroni corrected comparisons:■ H3K9me2 planned comparisons:0 mM 2-HG vs 10 mM 2-HG.0 mM 2-HG vs 20 mM 2-HG.20 mM 2-HG vs 5 mM α-KG + 20 mM 2-HG.■ H3K79me3 planned comparisons:0 mM 2-HG vs 10 mM 2-HG.0 mM 2-HG vs 20 mM 2-HG.20 mM 2-HG vs 5 mM α-KG + 20 mM 2-HG.Additional statistical analysis for comparison to the original reported data:○ Bonferroni corrected one-sample *t*-tests of normalized H3K9me2 levels of the following conditions compared to 1 (0 mM 2-HG):■ 10 mM 2-HG.■ 20 mM 2-HG.○ Bonferroni corrected one-sample *t*-tests of normalized H3K79me3 levels of the following conditions compared to constant (0 mM 2-HG set to 1):■ 10 mM 2-HG.■ 20 mM 2-HG.Meta-analysis of original and replication attempt effect sizes:○ Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-2-6}

The original racemic mixture of Oct-2-HG was synthesized in house by the original lab. The replicating lab is purchasing both L and R enantiomers and mixing them in equal amounts to form a racemic mixture.Aspects of the Western blot protocol are provided by the replicating lab; complete details of the original protocol were unavailable.

### Provisions for quality control {#s2-2-7}

All data obtained from the experiment---raw data, data analysis, control data and quality control data---will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/kvshc/>).STR profiling confirming cell line authenticity.Mycoplasma testing confirming lack of contamination.Images of stripped gel membranes confirming stripping was successful.

Protocol 3: Transfection of U-87 MG cells and determination of histone methylation by western blot {#s2-3}
--------------------------------------------------------------------------------------------------

This protocol describes the transfection of U-87 MG cells with the mutant form of IDH1 and assessing methylation by Western blot, as seen in Figure 3D and Supplemental Figure 3J.

### Sampling {#s2-3-1}

This experiment will be repeated independently 6 times for a final power of 94%.○ See Power calculations for details.Each experiment consists of 5 cohorts:○ Cohort 1: untransfected cells \[additional control\].○ Cohort 2: Vector transfected cells \[additional control\].○ Cohort 3: Vector transfected cells + vehicle.○ Cohort 4: IDH1^R132H^ transfected cells + vehicle.○ Cohort 5: IDH1^R132H^ transfected cells + 5 mM oct-α-KG.○ Each cohort is probed with antibodies against:■ H3.■ IDH1.■ H3K4me1.■ H3K4me3.■ H3K9me2.■ H3K27me2.

### Materials and reagents {#s2-3-2}

ReagentTypeManufacturerCatalog \#CommentsMouse monoclonal IgG~3~ α H3AntibodyAbcamab10799The original catalog number was not specifiedMouse monoclonal IgG~1~ α IDH1AntibodyAbcamab117976The original catalog number was not specifiedRabbit α H3K4me1AntibodyAbcamab8895The original catalog number was not specifiedMouse monoclonal IgG~2b~ α H3K4me3AntibodyAbcamab6000The original catalog number was not specifiedMouse monoclonal IgG~2a~ α H3K9me2AntibodyAbcamab1220The original catalog number was not specifiedRabbit α H3K27me2AntibodyAbcamab24684The original catalog number was not specifiedRabbit α H3K79me2AntibodyAbcamab3594The original catalog number was not specifiedU-87 MG cellsCellsATCCHTB-1460 mm tissue culture dishesMaterialCorning430166Or equivalentDMEM; high glucoseMediumSigma--AldrichD5671Original unspecifiedFBSReagentSigma--AldrichF2442Original unspecifiedEmpty vector plasmidPlasmidProvided by original authorsIDH1^R132H^ expression vectorPlasmidProvided by original authors*Trans*IT^®^-LT1 transfection reagentReagentMirus BioMIR 2300Replaces SunBio-EZ (SunBio)Oct-α-KGReagentCayman Chemical11970Typhoon scannerEquipmentGE HealthcareImageQuantSoftwareMolecular DynamicsVersion 5.2Protease inhibitor cocktail (mammalian)ReagentSigma--AldrichP8340-1MLOriginal not specifiedTruPAGE TEA-tricine SDS running buffer (20×)ReagentSigma--AldrichPCG3001-500 MLOriginal not specifiedTruPAGE LDS sample buffer (4×)ReagentSigma--AldrichPCG3009-10 MLOriginal not specifiedTruPAGE DTT sample reducer (10×)ReagentSigma--AldrichPCG3005-1MLOriginal not specifiedTruPAGE transfer buffer (20×)ReagentSigma--AldrichPCG3011-500 MLOriginal not specifiedPBS, without MgCl~2~ and CaCl~2~ReagentSigma--AldrichD8537Original not specifiedHybond ECL nitrocellulose membranes; 20 cm × 20 cmReagentGE Healthcare (Sigma--Aldrich)GERPN2020DOriginal not specifiedPonceau S solution; 0.1% (wt/vol) in 5% acetic acidReagentSigma--AldrichP7170Original not specifiedTris buffered saline (TBS); 10× solutionReagentSigma--AldrichT5912Original not specifiedBradford reagentReagentSigma--AldrichB6916Original not specifiedECL DualVue Western blotting markersReagentGE Healthcare (Sigma--Aldrich)GERPN810Original not specifiedECL prime Western blotting systemReagentGE Healthcare (Sigma--Aldrich)GERPN2232Original not specifiedGoat Anti-Rabbit IgG H&L (HRP)AntibodyAbcamab97051Goat Anti-Mouse IgG H&L (HRP)AntibodyAbcamab97023

### Procedure {#s2-3-3}

#### Notes {#s2-3-3-1}

U-87 MG cells are maintained in DMEM supplemented with 10% FBS at 37°C/5% CO~2~.All cells will be sent for mycoplasma testing and STR profiling.Plate U-87 MG cells in 60 mm dishes.24 hr after plating, transfect cells with plasmids (maxiprepped in Protocol 1) using *Trans*IT-LT1 Transfection Reagent according to manufacturer\'s protocol.a. ^\#^Transfect 8 µg of DNA per construct using appropriate volume of transfection reagent.i. Empty vector.ii. IDH1^R132H^ vector.48 hr after transfection, treat cells with vehicle or 5 mM Oct-α-KG for 6 hr.a. Vehicle is DMSO.Wash cells once with cold PBS, then lyse cells in 0.5 ml of SDS loading buffer.a. ^\#^4 SDS-PAGE loading buffer: 50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1% B-ME, 12.5 mM EDTA, 0.02% bromophenol blue.Heat lysates at 99°C for 10 min.Run SDS-PAGE gel until ladder marker reaches the bottom of the gel.^\#^Equilibrate gel in transfer buffer for 15 min.^\#^Meanwhile, cut membrane and 4 pieces 3 MM filter paper to size of gel.a. Soak membrane in MeOH for a few seconds, then wash with H~2~O.b. Soak membrane, 3 MM filter paper and pads in transfer buffer.i. Transfer buffer: 38 mM glycine, 47 mM Tris, 11 mM SDS, 20% MeOH.^\#^Assemble transfer cassette:a. red pole (+) \< clear plate \< pad \< 2 × 3 MM filter paper \< membrane \< gel \< 2 × 3 MM filter paper \< pad \< black pole (−).^\#^Add stirring bar and ice box to transfer box and fill box with transfer buffer until cassette is submerged.a. Run at 100 V for 1 hr.^\#^Wash membrane in wash buffer for 2 × 5 min.a. Wash buffer: 1× PBS with 0.05% Tween-20 and 0.1% sodium azide.^\#^Incubate membrane in blocking buffer for 30 min.a. Blocking buffer: 3% non-fat milk in PBS.^\#^Incubate membrane with primary antibody in blocking buffer for 2 hr at room temperature (RT) or overnight at 4°C (use manufacturer\'s suggested dilution in blocking buffer).a. H3.b. IDH1.c. H3K4me1.d. H3K4me3.e. H3K9me2.f. H3K27me2.g. H3K79me2.^\#^Wash 5 min 2× with wash buffer.^\#^Incubate membrane with secondary antibody for 90 min at RT (use manufacturer\'s suggested dilution in blocking buffer).a. HRP-conjugated Goat Anti-Mouse IgG H&L: 1:2000.b. HRP-conjugated Goat Anti-Rabbit IgG H&L: 1:2000.^\#^Wash 3 × 5 min in wash buffer.^\#^ Detect HRP-conjugated secondary antibodies with chemiluminescent detection according to the manufacturer\'s protocol and image on the Typhoon scanner.Strip the blot in between probes:a. Wash the membrane with 100 ml stripping buffer (100 mM betamercaptoethanol, 1% SDS 25 mM glycine pH 2.0) for 30 min with agitation.b. Wash the stripped membrane twice with Western blotting wash buffer, 600 ml each wash, for 10 min with agitation.c. Go to the blocking step of the western blot protocol.d. Check that stripping was successful by repeating the detection step (without re-probing). Record image of the stripped gel. This will confirm the first antibody-HRP conjugate is removed and/or inactivated. If the stripping procedure is successful, wash the membrane with washing buffer and repeat the blocking-probing and detection steps for the second antibody.i. Note: if stripping is unsuccessful, individual blots will be performed.Quantify intensity of bands on western blots using ImageQuant 5.2. Normalize levels of methylated histones to total H3 protein level. Normalize IDH1^R132H^ + vehicle and IDH1^R132H^ + oct-α-KG treated samples to vector + vehicle samples for each normalized methylated histone.Repeat independently 5 additional times.

### Deliverables {#s2-3-4}

Data to be collected:○ Full scans of western blots for H3, IDH1, H3K4me1, H3K4me3, H3K9me2, H3K27me2, and H3K79me2 (as seen in Figure 3D) including ladder.○ Raw values of intensity of western blot bands as measured by ImageQuant 5.2 software.○ Quantification of methylated histone values normalized to total protein level.○ Quantification of average values and standard deviations for each condition. Levels of methylated histone in vector control cells are set to 100% and levels of methylated histone for other conditions are relative to vector control.○ Table of average ± standard deviation of methylated histone levels normalized to H3 for each condition and relative to vector control cells (as seen in Supplemental Figure 3J).

### Confirmatory analysis plan {#s2-3-5}

Statistical analysis of the replication data:○ Note: At the time of analysis we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ One-way MANOVA of normalized H3K4me1, H3K4me3, H3K9me2, H3K27me2, and H3K79me2 levels from IDH1^R132H^ + vehicle and IDH1^R132H^ + oct-α-KG cells with the following Bonferroni corrected comparisons:■ H3K4me1 levels of IDH1^R132H^ vs IDH1^R132H^ + oct-α-KG.■ H3K4me3 levels of IDH1^R132H^ vs IDH1^R132H^ + oct-α-KG.■ H3K9me2 levels of IDH1^R132H^ vs IDH1^R132H^ + oct-α-KG.■ H3K27me2 levels of IDH1^R132H^ vs IDH1^R132H^ + oct-α-KG.■ H3K79me2 levels of IDH1^R132H^ vs IDH1^R132H^ + oct-α-KG.○ Bonferroni corrected one-sample *t*-tests (outside the MANOVA framework) of normalized levels from IDH1^R132H^ + vehicle of the following conditions compared to constant (vector + vehicle set to 100):○ H3K4me1.○ H3K4me3.○ H3K9me2.○ H3K27me2.○ H3K79me2.Meta-analysis of original and replication attempt effect sizes:○ Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-3-6}

While the manufacturer was specified for antibodies used, the exact catalog number was not. The RP:CB core team chose the most appropriate antibody from the manufacturer based on manufacturer\'s recommended applications and user reviews of the antibody.Aspects of the Western blot protocol are provided by the replicating lab; complete details of the original protocol were unavailable.

### Provisions for quality control {#s2-3-7}

All data obtained from the experiment---raw data, data analysis, control data and quality control data---will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/kvshc/>).STR profiling confirming cell line authenticity.Mycoplasma testing confirming lack of contamination.Images of stripped gel membranes confirming stripping was successful.

Protocol 4: Dot blot to measure of levels of 5hmC in genomic DNA {#s2-4}
----------------------------------------------------------------

This protocol describes how to transfect HEK293 cells with vectors expressing the catalytic domain of TET2 (TET2-CD) and wild-type or mutant forms of IHD1 and IDH2 and then assess genomic DNA hydroxymethylation by dot blot, as seen in Figure 7B and Supplemental Figure 7C.

Sampling {#s2-5}
--------

This experiment will be conducted independently 4 times for a final power of 96%.○ See Power calculations for details.Each experiment consists of 9 cohorts:○ Cohort 1: Untransfected cells \[additional control\].○ Cohort 2: Vector transfected cells.○ Cohort 3: FLAG-TET2-CD transfected cells.■ The catalytic domain of TET2.○ Cohort 4: FLAG-TET2-CM transfected cells.■ CM: mutant version of the TET2 catalytic domain.○ Cohort 5: FLAG-TET2-CD + FLAG-IDH1 transfected cells.○ Cohort 6: FLAG-TET2-CD + FLAG-IDH1^R132H^ transfected cells.○ Cohort 7: FLAG-TET2-CD + FLAG-IDH2 transfected cells.○ Cohort 8: FLAG-TET2-CD + FLAG-IDH2^R140Q^ transfected cells.○ Cohort 9: FLAG-TET2-CD + FLAG-IDH2^R172K^ transfected cells.○ Each cohort will have gDNA spotted out at 5, 10, 25, 50, 100 and 250 ng and probed with anti-5hmC antibody.

### Materials and reagents {#s2-5-1}

ReagentTypeManufacturerCatalog \#CommentsMouse monoclonal IgG~2a~ α Anti-5hmCAntibodyActive Motif40000Original catalog number unspecifiedMouse monoclonal IgG1 α FLAGAntibodySigma--AldrichF3165Original catalog number unspecifiedGoat Anti-Mouse IgG H&L (HRP)AntibodyAbcamab97023HEK293 cellsCellsATCCCRL-1573Original unspecifiedTyphoon scannerEquipmentAmersham/ GE Health Sciences9410Hybond ECL nitrocellulose membranes; 20 cm × 20 cmReagentGE Healthcare (Sigma--Aldrich)GERPN2020DOriginal not specifiedDMEM; high glucoseMediumSigma--AldrichD5671Original unspecifiedFBSReagentSigma--AldrichF2442Original unspecifiedVector alonePlasmidProvided by original authorsFLAG-TET2-CDPlasmidProvided by original authorsFLAG-TET2-CMPlasmidProvided by original authorsFLAG-IDH1PlasmidProvided by original authorsFLAG-IDH1^R132H^PlasmidProvided by original authorsFlag-IDH2PlasmidProvided by original authorsFLAG-IDH2^R140Q^PlasmidProvided by original authorsFLAG-IDH2^R172K^PlasmidProvided by original authors*Trans*IT-LT1 transfection reagentReagentMirus BioMIR 2300Replaces SunBio-EZ (SunBio)Nonfat-dried milk bovineReagentSigma--AldrichM7409ECL prime Western blotting systemReagentGE Healthcare (Sigma--Aldrich)GERPN2232Original not specifiedImage Quant 5.2SoftwareGEVersion 5.2Protease inhibitor cocktail (mammalian)ReagentSigma--AldrichP8340-1MLOriginal not specifiedTruPAGE TEA-Tricine SDS running buffer (20×)ReagentSigma--AldrichPCG3001-500 MLOriginal not specifiedTruPAGE LDS sample buffer (4×)ReagentSigma--AldrichPCG3009-10 MLOriginal not specifiedTruPAGE DTT sample reducer (10×)ReagentSigma--AldrichPCG3005-1MLOriginal not specifiedTruPAGE transfer buffer (20×)ReagentSigma--AldrichPCG3011-500 MLOriginal not specifiedPBS, without MgCl~2~ and CaCl~2~ReagentSigma--AldrichD8537Original not specifiedPonceau S solution; 0.1% (wt/vol) in 5% acetic acidReagentSigma--AldrichP7170Original not specifiedTris buffered saline (TBS); 10× solutionReagentSigma--AldrichT5912Original not specifiedBradford reagentReagentSigma--AldrichB6916Original not specifiedQIAamp DNA mini kitKitQiagen51304

### Procedure {#s2-5-2}

#### Notes {#s2-5-2-1}

This protocol contains information from Ito and colleagues ([@bib6]).HEK293 cells are maintained in DMEM supplemented with 10% FBS at 37°C/5% CO~2~.All cells will be sent for mycoplasma testing and STR profiling.Transform, grow up and maxiprep plasmids using an Endo-free Maxiprep kit following the manufacturer\'s instructions.a. Confirm plasmid identity by sequencing.Plate 6 × 10^5^ − 1.2 × 10^6^ HEK293 cells per 60 mm dish.24 hr after plating, transfect cells with indicated plasmids.a. ^\#^Transfect cells with 8 µg of DNA per construct using *Trans*IT-LT1 Transfection Reagent according to manufacturer\'s protocol^\#^.i. Cohort 1: Untransfected cells.ii. Cohort 2: Vector only.iii. Cohort 3: FLAG-TET2-CD.iv. Cohort 4: FLAG-TET2-CM.v. Cohort 5: FLAG-TET2-CD + FLAG-IDH1.vi. Cohort 6: FLAG-TET2-CD + FLAG-IDH1^R132H^.vii. Cohort 7: FLAG-TET2-CD + FLAG-IDH2.viii. Cohort 8: FLAG-TET2-CD + FLAG-IDH2^R140Q^.ix. Cohort 9: FLAG-TET2-CD + FLAG-IDH2^R172K^.^\*^For each cohort, transfect two parallel plates; harvest genomic DNA from one plate (proceed to Step 5) and protein from the second plate (proceed to Step 7).36--40 hr after transfection, isolate genomic DNA from cells on the first plate using the QIAamp kit according to the manufacturer\'s instructions.a. Determine DNA concentration and purity.Dot blot to assess levels of 5hmC:a. Quantify gDNA concentration using a NanoDrop. ^\#^Spot genomic DNA onto nitrocellulose membrane using a pipet, then crosslink the DNA to the membrane by UV irradiation for 2 min.i. The following amounts of genomic DNA should be spotted: 250 ng, 100 ng, 50 ng, 25 ng, 10 ng, and 5 ng.b. Bake nitrocellulose membrane at 80°C for ^\#^1 hr.c. Block membrane with 5% skim milk in TBS with 0.1% Tween 20 (TBST) for 1 hr.d. Perform western blot on spotted nitrocellulose with the following antibody: anti-5hmC. Incubate membrane with primary antibody diluted 1:10,000 overnight at 4°C.e. Wash membrane three times with TBST.f. Incubate membrane with secondary antibody (HRP-conjugated anti-rabbit IgG) diluted 1:2000 for 1 hr at room temperature.g. Wash membrane three times with TBST, then treat with ECL and scan with a Typhoon scanner.h. Quantify dot-blot using Image-Quanta software.Check expression of exogenous proteins by Western blot using the second plate.a. Wash cells once with cold PBS, then lyse cells in 0.5 ml of SDS loading buffer.i. ^\#^4× SDS-PAGE loading buffer: 50 mM Tris pH 6.8, 2% SDS, 10% glycerol, 1% B-ME, 12.5 mM EDTA, 0.02% bromophenol blue.b. Heat lysates at 99°C for 10 min.c. Run SDS-PAGE gel until ladder marker reaches the bottom of the gel.d. ^\#^Equilibrate gel in transfer buffer for 15 min.e. ^\#^Meanwhile, cut membrane and 4 pieces 3 MM filter paper to size of gel.i. Soak membrane in MeOH for a few seconds, then wash with H~2~O.ii. Soak membrane, 3 mM filter paper and pads in transfer buffer.iii. Transfer buffer: 38 mM glycine, 47 mM Tris, 11 mM SDS, 20% MeOHf. ^\#^Assemble transfer cassette:i. red pole (+) \< clear plate \< pad \< 2 × 3 MM filter paper \< membrane \< gel \< 2 × 3 MM filter paper \< pad \< black pole (−).g. ^\#^Add stirring bar and ice box to transfer box and fill box with transfer buffer until cassette is submerged.i. Run at 100 V for 1 hr.h. ^\#^Wash membrane in wash buffer for 2 × 5 min.i. Wash buffer: 1× PBS with 0.05% Tween-20 and 0.1% sodium azide.i. ^\#^Incubate membrane in blocking buffer for 30 min.i. Blocking buffer: 3% non-fat milk in PBS.j. ^\#^Incubate membrane with primary antibody in blocking buffer for 2 hr at RT or O/N at 4°C (use manufacturer\'s suggested dilution in blocking buffer).i. α FLAG.k. ^\#^Wash 5 min 2× with wash buffer.l. ^\#^Incubate membrane with secondary antibody for 90 min at RT (use manufacturer\'s suggested dilution in blocking buffer).i. HRP-conjugated Goat Anti-Mouse IgG H&L: 1:2000.m. ^\#^Wash 3 × 5 min in wash buffer.n. ^\#^ Detect HRP-conjugated secondary antibodies with chemiluminescent detection according to the manufacturer\'s protocol and image on the Typhoon scanner.o. Quantify intensity of dots on western blots using ImageQuant 5.2.i. Normalize values to FLAG-TET2-CD transfected cells.Repeat independently three additional times.

### Deliverables {#s2-5-3}

Data to be collected:○ Chromatograms and sequence files confirming plasmid identity.○ DNA concentration and purity data.○ Full scans of dot blots for anti-5hmC and western blots for anti-FLAG (as seen in Figure 7B).○ Raw values of intensity of dot blot as measured by Image-Quanta software.○ Quantification of 5hmc values relative to TET2-CD.○ Quantification of average values and standard deviations for each condition for all experiments.○ Bar graph and table of average values and standard deviations relative to TET2-CD samples (as seen in Figure 7B and Supplemental Figure 7C).

### Confirmatory analysis plan {#s2-5-4}

Statistical analysis of the replication data:○ Note: At the time of analysis we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ Comparison of the various genotypes for each of the DNA concentrations.■ Bonferonni corrected one-sample *t*-test of normalized 5hmC levels of the following cohorts compared to constant (TET2-CD set to 1):TET-2CD + IDH1.TET-2CD + IDH1^R132H^.TET-2CD + IDH2.TET-2CD + IDH2^R140Q^.TET-2CD + IDH2^R172K^.Meta-analysis of original and replication attempt effect sizes:○ Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.

### Known differences from the original study {#s2-5-5}

Aspects of the Western blot protocol are provided by the replicating lab; complete details of the original protocol were unavailable.

### Provisions for quality control {#s2-5-6}

All data obtained from the experiment---raw data, data analysis, control data and quality control data---will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/kvshc/>).Sequence data confirming plasmid identity.Western blots confirming exogenous protein expression.STR profiling confirming cell line authenticity.Mycoplasma testing confirming lack of contamination.

Protocol 5: Radiolabeled 5mC-5hmC conversion assay {#s2-6}
--------------------------------------------------

This protocol describes how to run the in vitro assay to examine the effect of 2-HG on the TET family of methyl hydroxylases, as seen in Figure 8A.

### Sampling {#s2-6-1}

This experiment will be performed independently a total of 6 times for a final power of ≥80%.○ The original data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.○ See Power calculations for details.Each experiment consists of 8 cohorts:○ No recombinant protein.○ FLAG-TET2-CD + vehicle.○ FLAG-TET2-CD + 10 mM D-2-HG.○ FLAG-TET2-CD + 25 mM D-2-HG.○ FLAG-TET2-CD + 50 mM D-2-HG.○ FLAG-TET2-CD + 10 mM L-2-HG.○ FLAG-TET2-CD + 25 mM L-2-HG.○ FLAG-TET2-CD + 50 mM L-2-HG.○ Each cohort will detect:■ 5m-dCMP.■ 5hm-dCMP.

### Materials and reagents {#s2-6-2}

ReagentTypeManufacturerCatalog \#CommentsD-2-HGReagentSigma--AldrichH8378L-2-HGReagentSigma--Aldrich90790Sf9 cellsCellsATCCCRL-1711Original unspecifiedShrimp alkaline phosphataseReagentNew England BiolabsMO371ST4 polynucleotide kinaseReagentSigma--AldrichKEM0006DNase IReagentSigma--AldrichAMPD1Phosphodiesterase IReagentSigma--AldrichP3243PEI-cellulose TLC plateMaterialSigma--AldrichZ122882FLAG-TET2-CD viral particlesVirusProvided by the original authorsAnti-Flag M2 antibody agarose affinity gelReagentSigma--AldrichA2220Flag peptideReagentSigma--AldrichF4799α-KGReagentSigma--Aldrich75,892GenElute PCR Clean-Up KitKitSigma--AldrichNA1020-1KTReplaces Qiagen cat no. 28304\[γ-32\]ATPReagentPerkin ElmerBLU502H/NEG502HMspI methyltransferaseReagentNEBM0215LMspI restriction endonucleaseReagentNEBR0106TDNA duplex oligonucleotide substrateoligoIntegrated DNA Technologiescustom 5′-GTGTTCTTTCAGCTCCGGTCACGCTGACCAGC-3′ as a duplex oligo, HPLC purified at 1 umole scale maybe higher depending on recoveryM13-F primeroligoIntegrated DNA TechnologiesCCAGTCACGACGTTGTAAAACGM13-R primeroligoIntegrated DNA TechnologiesCCAGTCACGACGTTGTAAAACGJumpStart REDTaq DNA PolymeraseReagentSigmaD8189-50UNdNTP mix 10 mMReagentSigmaD7295-.2 MLBlueView TAE bufferBufferSigmaT8935-1LMolecular biology grade waterReagentSigmaW4502-1L

### Procedure {#s2-6-3}

Note: This protocol contains information from Ito and colleagues (2010).Generate recombinant FLAG-TET2-CD virus from supplied virus stock.a. ^\#^Infect a 5 ml culture with 0.1 ml of virus stock supplied.i. Grow in a stationary tissue culture flask at 27°C.b. ^\#^After 5 days, collect the virus. Simultaneously, start a 50 ml suspension culture at 27°C with 140 rpm shaking.i. Confirm viral insert identity by sequencing using M13F and R primers and REDTaq polymerase, followed by gel purification and sequencing of PCR product.c. ^\#^After culturing for 3 days, infected the suspension culture with 2.5 ml of virus stock.d. ^\#^4 days after infection collect virus. Simultaneously, start new 50 ml suspension cultures for protein expression.e. ^\#^After 3 days of culture, the suspension cultures are infected with 2.5 ml virus.e. ^\#^After 3 days of infection the cells expressing recombinant protein are collected by centrifugation and stored at −80°C until the protein is to be purified.i. ^\#^More round of expression may be required depending on expression level.f. Purify baculovirus expressed recombinant FLAG-TET2-CD from insect Sf9 cells with anti-Flag M2 antibody agarose affinity gel and elute with buffer containing 10 mM Tris--HCl pH 8.0, 150 mM NaCl, 1 mM DTT, 15% glycerol and 0.2 μg/µl Flag peptide.g. Note; generate sufficient recombinant protein to use in a total of 6 replicates of this protocol.^\#^Prepare methylated oligonucleotide substrate.a. Treat unmethylated DNA duplex oligo with MspI methyltransferase for 2 hr at 37°C following manufacturer\'s instructions.b. Purify with a QiaQuick Nucleotide Removal kit following manufacturer\'s instructions.Incubate 5 µg of the purified recombinant TET2-CD protein and various concentrations of vehicle only, D-2-HG, or L-2-HG with 0.5 μg methylated oligonucleotide substrate in vehicle (50 mM HEPES (pH 8), 75 μM Fe(NH~4~)~2~(SO~4~)~2~, 2 mM ascorbate) and 0.1 mM α-KG for 3 hr at 37°C.a. See cohorts for detailed concentrations to use.b. ^\#^If necessary, concentrate protein to ensure the final reaction volume is between 100--1000 µl.c. Purify oligonucleotide substrates using a GenElute PCR Clean-Up Kit following manufacture\'s instructions.Digest oligonucleotides with 1 U/μg MspI restriction endonuclease at 37°C for ^\#^2 hr following manufacturer\'s instructions.Treat digested DNA with 1U/μmol shrimp alkaline phosphatase at 37°C for ^\#^2 hr.a. ^\#^Heat inactivate at 65°C for 10 min.Label DNA with \[γ-32\]ATP and polynucleotide kinase.a. ^\#^Add 1 µl of \[γ-32\]ATP at 3000 Ci/mmol, 5 mCi/ml and 1 µl polynucleotide kinase to the previous reaction.b. ^\#^Incubate for 1 hr at 37°C.Ethanol precipitate labeled fragments.i. ^\#^Add 3M NaOAc to a final concentration of 0.3M.ii. ^\#^Add 2 vol 100% EtOH.iii. ^\#^Incubate mixture at on dry ice for 20 min.iv. ^\#^Centrifuge in a microfuge at 4°C at maximum speed for 10 min.v. ^\#^Remove supernatant and air dry pellet.vi.^\#^Resuspend.Digest labeled fragments with 10 µg DNAse I and 10 μg phosphodiesterase I in the presence of 15 mM MgCl~2~ and 2 mM CaCl~2~ at 37 °C for ^\#^2 hr.Spot 1 µl of digestion product from step 8 onto a PEI-cellulose TLC plate and separate in an isobutyric acid/water/ammonium hydroxide (66:20:2) buffer.Dry the TLC plate and then expose to film.Quantify intensity of 5hmC bands.a. Normalize values to FLAG-TET2-CD + vehicle.Repeat independently five additional times starting at Step 2.

### Deliverables {#s2-6-4}

Data to be collected:○ Sequencing data confirming viral insert identity.○ Data about viral titer and amount of and quality of protein generated.○ Scans of films exposed to TLC plate (as in Figure 8A, left).○ Raw values of intensity of 5hm-dCMP (5hmC) spots.○ Quantification of 5hmC intensity relative to FLAG-TET2-CD (recombinant protein) + vehicle sample.○ Quantification of average values and standard deviations for each condition for triplicate experiments.○ Bar graph of relative 5hmC intensity for each sample with standard deviations (as in Figure 8A, right).

### Confirmatory analysis plan {#s2-6-5}

Statistical Analysis of the Replication Data:○ Note: At the time of analysis we will perform the Shapiro--Wilk test and generate a quantile--quantile plot to assess the normality of the data. We will also perform Levene\'s test to assess homoscedasticity. If the data appears skewed we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test.○ Two-way ANOVA of normalized 5hmC levels of TET2-CD protein treated with D-2-HG or L-2-HG with the following Bonferroni corrected comparisons:10 mM D-2-HG vs 10 mM L-2-HG.50 mM D-2-HG vs 50 mM L-2-HG.10 mM D-2-HG vs 50 mM D-2-HG.○ Bonferroni corrected one-sample *t*-tests (outside the ANOVA framework) of normalized 5hmC levels of TET2-CD protein treated with the following concentrations of D-2-HG compared to constant (TET2-CD + vehicle set to 1):10 mM D-2-HG.50 mM D-2-HG.Meta-analysis of original and replication attempt effect sizes:○ The replication data (mean and 95% confidence interval) will be plotted with the original reported data value plotted as a single point on the same plot for comparison.

### Known differences from the original study {#s2-6-6}

The lab provided the protocol for expansion of the viral aliquot shared by the original authors for generation of the recombinant FLAG-TET2 protein.

### Provisions for quality control {#s2-6-7}

All data obtained from the experiment---raw data, data analysis, control data and quality control data---will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/kvshc/>).Sequence data confirming viral insert identity.Data about viral titer and amount of and quality of protein generated.

#### Power calculations {#s2-6-7-1}

Power calculations are performed to calculate the number of samples required to achieve at least 80% power and the indicated alpha error. For a detailed breakdown of all power calculations, please see spreadsheet at <https://osf.io/gnsti/wiki/home/>.

### Protocol 1 {#s2-6-8}

#### Summary of original data {#s2-6-8-1}

Note: Data estimated from published figures.Supp. Figure 3I: Levels of α-KG with WT or mutant IDH1MeanSDNVector-transfected U-87 MG cells840[\*](#tblfn1){ref-type="table-fn"}2WT IDH-transfected U-87 MG cells1207.82IDH^R132H^-transfected U-87 MG cells41142Supp. Figure 3I: Levels of 2-HG with WT or mutant IDH1.MeanSDNVector-transfected U-87 MG cells900[\*](#tblfn1){ref-type="table-fn"}2WT IDH-transfected U-87 MG cells1400[\*](#tblfn1){ref-type="table-fn"}2Mutant IDH-transfected U-87 MG cells1730142[^1]

#### Test family {#s2-6-8-2}

Due to a lack of raw original data, we are unable to perform power calculations using a MANOVA. We are determining sample size calculations using a two-way ANOVA.Two-way ANOVA followed by Bonferroni corrected comparisons.

#### Power calculations {#s2-6-8-3}

Calculations were performed with R software, version 3.1.2 ([@bib10]) and G\*Power software, version 3.1.7 ([@bib4]).ANOVA calculations; α = 0.05F(1,6) metabolitePartial η2Effect size *f*PowerTotal sample size6702.30.99910633.4300599.9%7\*[^2]Corrected *t*-test sample size calculations; α = 0.0083333Group 1Group 2Effect size *d*PowerSample size per groupα-KGVectorIDH1-WT3.5781580.1%[\*](#tblfn3){ref-type="table-fn"}4[\*](#tblfn3){ref-type="table-fn"}VectorIDH1-R132H3.3096092.0%5IDH1-WTIDH1-R132H6.9712597.4%[†](#tblfn4){ref-type="table-fn"}3[†](#tblfn4){ref-type="table-fn"}2HGVectorIDH1-WT4.2016893.1%[‡](#tblfn5){ref-type="table-fn"}4[‡](#tblfn5){ref-type="table-fn"}VectorIDH1-R132H126.2266999.9%[§](#tblfn6){ref-type="table-fn"}2[§](#tblfn6){ref-type="table-fn"}IDH1-WTIDH1-R132H122.3783299.9%[\#](#tblfn7){ref-type="table-fn"}2[\#](#tblfn7){ref-type="table-fn"}[^3][^4][^5][^6][^7]

#### Sensitivity calculations {#s2-6-8-4}

Comparing 2-HG levels from Vector to IDH1 WT:○ Based on a sample size of 4 per group, we will be able to see an effect size of 3.3710662 with α = 0.01 and a power of 80%.

### Protocol 2 {#s2-6-9}

#### Summary of original data {#s2-6-9-1}

Note: Data estimated from published figures.Supp. Fig. 3F: Quantification of Figure 3A Western BlotsMeanSDNUntreated cellsH3K9me2/H3 ratio103H3K79me2/H3 ratio10310 mM oct-2-HG treated cellsH3K9me2/H3 ratio3.80.53H3K79me2/H3 ratio8.51.5320 mM oct-2-HG treated cellsH3K9me2/H3 ratio5.50.33H3K79me2/H3 ratio17.22.4320 mM oct-2-HG + 5 mM oct-α-KG treated cellsH3K9me2/H3 ratio0.60.33H3K79me2/H3 ratio0.90.33

#### Test family {#s2-6-9-2}

Due to a lack of raw original data, we are unable to perform power calculations using a MANOVA. We are determining sample size calculations using a two-way ANOVA.Two-way ANOVA followed by Bonferroni corrected comparisons.

#### Power calculations {#s2-6-9-3}

Calculations were performed with R software, version 3.1.2 ([@bib10]) and G\*Power software, version 3.1.7 ([@bib4]).ANOVA calculations; α = 0.05F(1,16) histonePartial η2Effect size *f*A priori powerTotal sample size235.02000.9362603.8325999.9%[\*](#tblfn8){ref-type="table-fn"}10[\*](#tblfn8){ref-type="table-fn"}[^8]Corrected *t*-tests sample size calculations; α = 0.0083Group 1Group 2Effect size *d*PowerSample size per groupH3K9me2Vehicle treated cells10 mM Oct-2-HG treated cells11.0593499.9%3H3K79me28.9228899.9%3H3K9me2Vehicle treated cells20 mM Oct-2-HG treated cells23.5540899.9%3H3K79me214.2406999.9%3H3K9me220 mM Oct-2-HG treated cells20 mM Oct-2-HG + 5 mM oct-α-KG treated cells28.8235399.9%3H3K79me216.4612999.9%3

#### Test family {#s2-6-9-4}

This is an additional analysis to allow a direct comparison with the original study.Bonferroni corrected one-sample *t*-tests compared to 1 (vehicle treated cells).

#### Power calculations {#s2-6-9-5}

Calculations were performed with G\*Power software, version 3.1.7 ([@bib4]).Bonferroni corrected t-tests; α = 0.0083GroupConstantEffect size dA Priori powerSample size per groupH3K9me210 mM Oct-2-HG treated cells19.6551790.3%3H3K79me28.6206984.4%3H3K9me220 mM Oct-2-HG treated cells126.4705999.9%3H3K79me211.65468o 96.6%3

### Protocol 3 {#s2-6-10}

#### Summary of original data {#s2-6-10-1}

Note: Data estimated from published figure.Supp. Figure 3J: quantification of Western blot band intensities from Figure 3D normalized to vector controlMeanSDNWith vector + vehicleH3K4me1/H3 ratio100Unspecified3H3K4me3/H3 ratio100unspecified3H3K9me3/H3 ratio100unspecified3H3K27me2/H3 ratio100unspecified3H3K79me2/H3 ratio100unspecified3With IDH1^R132H^ + vehicleH3K4me1/H3 ratio209363H3K4me3/H3 ratio466643H3K9me3/H3 ratio283563H3K27me2/H3 ratio232243H3K79me2/H3 ratio267473With IDH1^R132H^ and oct-α-KGH3K4me1/H3 ratio105163H3K4me3/H3 ratio274253H3K9me3/H3 ratio126213H3K27me2/H3 ratio9993H3K79me2/H3 ratio130203

#### Test family {#s2-6-10-2}

Due to a lack of raw original data, we are unable to perform power calculations using a MANOVA. We are determining sample size calculations using a two-way ANOVA.Two-way ANOVA followed by Bonferroni corrected comparisons.

#### Power calculations {#s2-6-10-3}

Calculations were performed with R software, version 3.1.2 ([@bib10]) and G\*Power software, version 3.1.7 ([@bib4]).ANOVA calculations; α = 0.05F(1,20) cell treatmentsPartial η2effect size *f*PowerTotal Sample size119.56290.856702.4450297.1%[\*](#tblfn9){ref-type="table-fn"}12[\*](#tblfn9){ref-type="table-fn"}[^9]Corrected *t*-test sample size calculations; α = 0.005Group 1Group 2HistoneEffect size *d*PowerSample size per groupIDH1^R132H^ + vehicleIDH1^R132H^ + oct-α-KGH3K4me1/H3 ratio3.7333894.2%[\*](#tblfn10){ref-type="table-fn"}5[\*](#tblfn10){ref-type="table-fn"}H3K4me3/H3 ratio3.9518482.1%[†](#tblfn11){ref-type="table-fn"}4[†](#tblfn11){ref-type="table-fn"}H3K9me3/H3 ratio3.7124093.9%[‡](#tblfn12){ref-type="table-fn"}5[‡](#tblfn12){ref-type="table-fn"}H3K27me2/H3 ratio7.3381195.0%[§](#tblfn13){ref-type="table-fn"}3[§](#tblfn13){ref-type="table-fn"}H3K79me2/H3 ratio3.7931494.9%[\#](#tblfn14){ref-type="table-fn"}5[\#](#tblfn14){ref-type="table-fn"}[^10][^11][^12][^13][^14]

#### Test family {#s2-6-10-4}

Outside the ANOVA frameworkBonferroni corrected one-sample *t*-tests compared to 1 (vector + vehicle).

#### Power calculations {#s2-6-10-5}

Calculations were performed with G\*Power software, version 3.1.7 ([@bib4]).Corrected *t*-test sample size calculations; α = 0.005Group 1ConstantHistoneEffect size *d*PowerSample size per groupIDH1^R132H^ + vehicle100H3K4me1/H3 ratio3.0277894.2%6H3K4me3/H3 ratio5.7187592.2%[\*](#tblfn15){ref-type="table-fn"}4[\*](#tblfn15){ref-type="table-fn"}H3K9me3/H3 ratio3.2678682.9%[†](#tblfn16){ref-type="table-fn"}5[†](#tblfn16){ref-type="table-fn"}H3K27me2/H3 ratio5.5000090.2%[‡](#tblfn17){ref-type="table-fn"}4[‡](#tblfn17){ref-type="table-fn"}H3K79me2/H3 ratio3.5531988.8%[§](#tblfn18){ref-type="table-fn"}5[§](#tblfn18){ref-type="table-fn"}[^15][^16][^17][^18]

### Protocol 4 {#s2-6-11}

#### Summary of original data {#s2-6-11-1}

○ Note: Values estimated from published figure.Figure 7B: Relative 5hmC intensityMeanSDN50 ng Genomic DNAVector00.013TET2-CD103TET2-CM00.013TET2-CD + IDH12.50.33TET2-CD + IDH1^R132H^0.290.13TET2-CD + IDH22.60.113TET2-CD + IDH2^R40Q^0.310.073TET2-CD + IDH2^R172K^0.310.093

#### Test family {#s2-6-11-2}

Bonferroni corrected one-sample *t*-tests compared to 1 (TET2-CD).

#### Power calculations {#s2-6-11-3}

Power calculations were performed using G\*Power software, version 3.1.7 ([@bib4]).Corrected *t*-test sample size calculations; α = 0.01Group 1: TET2 +ConstantEffect size *d*PowerSample size per groupIDH115.0000095.9%4IDH1^R132H^17.1000099.9%4IDH2114.5454599.8%[\*](#tblfn19){ref-type="table-fn"}3[\*](#tblfn19){ref-type="table-fn"}IDH2^R140Q^19.8571494.6%[†](#tblfn20){ref-type="table-fn"}3[†](#tblfn20){ref-type="table-fn"}IDH2^R172K^17.6666782.9%[‡](#tblfn21){ref-type="table-fn"}3[‡](#tblfn21){ref-type="table-fn"}[^19][^20][^21]

### Protocol 5 {#s2-6-12}

#### Summary of original data {#s2-6-12-1}

Note: Data estimated from published figures.Figure 8A: TLC blot intensitiesMeanTET2 + vehicle1TET2 + 10 mM D-2-HG0.67TET2 + 25 mM D-2-HG0.45TET2 + 50 mM D-2-HG0.17TET2 + 10 mM L-2-HG0.05TET2 + 25 mM L-2-HG0.03TET2 + 50 mM L-2-HG0.03

#### Test family {#s2-6-12-2}

One way ANOVA followed by Bonferroni corrected comparisons.Outside the ANOVA framework○ Bonferroni corrected one-sample *t*-tests compared to 1 (TET2 + vehicle).

#### Power calculations {#s2-6-12-3}

Because the original data presented does not have variance (s.e.m. or s.d.), we have performed power calculations using several different levels of calculated variance and an assumed number of replicates to determine a suitable number of replications to perform.Calculations were performed with R software, version 3.1.2 ([@bib10]) and G\*Power software, version 3.1.7 ([@bib4]).Calculated variances and assumed NFigure 8A: dot blot intensitiesMeanN2%15%28%40%TET2 + vehicle13n/a[\*](#tblfn22){ref-type="table-fn"}n/a[\*](#tblfn22){ref-type="table-fn"}n/a[\*](#tblfn22){ref-type="table-fn"}n/a[\*](#tblfn22){ref-type="table-fn"}TET2 + 10 mM D-2-HG0.6730.01340.10050.18760.268TET2 + 25 mM D-2-HG0.4530.0090.06750.1260.18TET2 + 50 mM D-2-HG0.1730.00340.02550.04760.068TET2 + 10 mM L-2-HG0.0530.0010.00750.0140.02TET2 + 25 mM L-2-HG0.0330.00060.00450.00840.012TET2 + 50 mM L-2-HG0.0330.00060.00450.00840.012[^22]

### 2% variance {#s2-6-13}

ANOVA calculations; α = 0.05F(2,12) interactionPartial η2Effect size *f*PowerTotal sample size1910.60.9968717.843498.2%[\*](#tblfn23){ref-type="table-fn"}9[\*](#tblfn23){ref-type="table-fn"}[^23]Corrected *t*-test sample size calculations; α = 0.01Group 1Group 2Effect size *d*PowerSample size per group10 mM D-2-HG10 mM L-2-HG65.2523199.9%250 mM D-2-HG50 mM L-2-HG57.3462399.9%210 mM D-2-HG50 mM D-2-HG51.1483999.9%2Corrected *t*-test sample size calculations; α = 0.01Group 1:ConstantEffect size *d*PowerSample size per group10 mM D-2-HG124.6268797.7%250 mM D-2-HG1244.1176599.9%2

### 15% variance {#s2-6-14}

ANOVA calculations; α = 0.05F(2,12) interactionPartial η2Effect size *f*PowerTotal sample size2.379300.849872.3793093.8%12[\*](#tblfn24){ref-type="table-fn"}[^24]Corrected *t*-test sample size calculations; α = 0.01Group 1Group 2Effect size *d*PowerSample size per group10 mM D-2-HG10 mM L-2-HG8.7003199.9%350 mM D-2-HG50 mM L-2-HG7.6461699.4%310 mM D-2-HG50 mM D-2-HG6.8197897.9%3Corrected *t*-test sample size calculations; α = 0.01Group 1:ConstantEffect size *d*PowerSample size per group10 mM D-2-HG13.2835887.2%650 mM D-2-HG132.5490299.5%3

### 28% variance {#s2-6-15}

ANOVA calculations; α = 0.05F(2,12) interactionPartial η2Effect size *f*PowerTotal sample size9.75480.619161.2750786.1%12Corrected t-test sample size calculations; α = 0.01Group 1Group 2Effect size *d*PowerSample size per group10 mM D-2-HG10 mM L-2-HG4.6608897.9%450 mM D-2-HG50 mM L-2-HG4.0961693.6%410 mM D-2-HG50 mM D-2-HG3.6534686.6%4Corrected *t*-test sample size calculations; α = 0.01Group 1:ConstantEffect size *d*PowerSample size per group10 mM D-2-HG11.7590680.3%1450 mM D-2-HG117.4369794.0%4

### 40% variance {#s2-6-16}

ANOVA calculations; α = 0.05F(2,12) interactionPartial η2Effect size *f*PowerTotal sample size4.77650.443230.89223782.2%17[\*](#tblfn25){ref-type="table-fn"}[^25]Corrected *t*-test sample size calculations; α = 0.01Group 1Group 2Effect size *d*PowerSample size per group10 mM D-2-HG10 mM L-2-HG3.2626292.8%550 mM D-2-HG50 mM L-2-HG2.8673183.9%510 mM D-2-HG50 mM D-2-HG2.5574286.3%6Corrected *t*-test sample size calculations; α = 0.01Group 1:ConstantEffect size *d*PowerSample size per group10 mM D-2-HG11.2313480.8%2750 mM D-2-HG112.2058884.6%5[^26]
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled "Registered report: Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases" for peer review at *eLife*. Your submission has been favorably evaluated by Michael Marletta (Senior editor), Irwin Davidson (Reviewing editor), and four reviewers.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission. The reviewers of this paper have raised several issues and we would ask you to specifically take into account the comments concerning the statistical analyses.

Summary:

The article outlines the detailed protocol to reproduce a report published in *Cancer* Cell linking mutations in IDH1/2 to cellular levels of Ketoglutarate and changes in histone and DNA methylation. This initial work had a major impact on linking metabolites to chromatin, but also raised a number of questions that justify a rigorous replication.

Overall, the proposed study covers the major aspects with the required detail and rigour.

Specific points to address are:

1\) The referees suggest that the authors consider using mass spectrometry to measure 5hmC in addition to immune dot-blot. Mass spectrometry is a more quantitative measure and while it would go beyond replicating the published findings it might give a clearer answer.

2\) In protocol 1 a 2-way ANOVA is proposed, however as 2 quantitative variables are measured and there is only one qualitative factor (with three possible values) influencing these measures, an MANOVA would be more suited.

3\) There may be confusion between groups and variables in setting the degrees of freedom for ANOVA analyses. In protocol 1, how was (2, 6) obtained? The same question applies to protocols 3, 4 and 5.

4\) In addition to *t*-tests for the comparison of means where both variances are equal, F-tests should be added when variances are significantly different.

5\) Referees raised concerns about null variances that appear in the power calculation tables. Although these values are not always available, variance values can change the conclusion of the tests. When variances are not available, preliminary experiments in order to estimate them are proposed. More generally, variance values used in this paper are estimated from published figures using a low number of replicates, so they are not robust. A way to increase robustness would be to increase measured values by a pre-determined factor and then relax the expected power if too many replicates are required.

Also, non-rounded computed sample sizes are requested to have an idea of how close we are to the theoretical value after rounding.

6\) For protocol 2, in subsection "Confirmatory analysis plan", a MANOVA is proposed, whereas a one-way ANOVA is suggested for the same protocol in subsection "Test family". Please correct this inconsistency.

7\) Protocol 5: a mean across several groups is compared with the mean of a single group. This should not be done with a simple *t*-test to take into account the fact that the number of measures is different in the two groups being compared.

10.7554/eLife.07420.003

Author response

*1) The referees suggest that the authors consider using mass spectrometry to measure 5hmC in addition to immune dot-blot. Mass spectrometry is a more quantitative measure and while it would go beyond replicating the published findings it might give a clearer answer*.

We agree mass spectrometry analysis would be a more quantitative approach to measure 5hmC levels, however feel it is beyond the scope of this project, which is to perform a direct replication of the original experiment(s). Aspects of an experiment not included in the original study are occasionally added to ensure the quality of the research, but by no means is a requirement of this project; rather, it is an extension of the original work. We know that the exclusion of certain experiments limits the scope of what can be analyzed by the project, but we are attempting to identify a balance of breadth of sampling for general inference with sensible investment of resources on replication projects to determine to what extent the included experiments are reproducible.

2\) In protocol 1 a 2-way ANOVA is proposed, however as 2 quantitative variables are measured and there is only one qualitative factor (with three possible values) influencing these measures, an MANOVA would be more suited.

We agree and have included this in the confirmatory analysis section. However, as we do not have the raw data needed to perform a power calculation for the MANOVA test, we performed it with a 2-way ANOVA to estimate the needed sample size and adjusted the alpha error for the planned contrasts that will be performed to ensure the sample size is sufficient.

*3) There may be confusion between groups and variables in setting the degrees of freedom for ANOVA analyses. In protocol 1, how was (2, 6) obtained? The same question applies to protocols 3, 4 and 5*.

Thank you for catching these inconsistencies, we have checked and adjusted each protocol in regards to degrees of freedom. Some of the analysis sections have changed to address other questions below, but a link to all scripts has been provided below and in the revised manuscript.

*4) In addition to* t*-tests for the comparison of means where both variances are equal, F-tests should be added when variances are significantly different*.

We have added a note in the analysis section that at the time of analysis, we will assess the normality and homoscedasticity of the data. If necessary, we will perform the appropriate transformation in order to proceed with the proposed statistical analysis. We will note any changes or transformations made. We have updated the manuscript to address this point.

*5) Referees raised concerns about null variances that appear in the power calculation tables. Although these values are not always available, variance values* can *change the conclusion of the tests. When variances are not available, preliminary experiments in order to estimate them are proposed. More generally, variance values used in this paper are estimated from published figures using a low number of replicates, so they are not robust. A way to increase robustness would be to increase measured values by a pre-determined factor and then relax the expected power if too many replicates are required*.

*Also, non-rounded computed sample sizes are requested to have an idea of how close we are to the theoretical value after rounding*.

We agree about the concern about null variances and have reanalyzed the proposed analysis plans and power calculations to reflect this. In many cases the reason for the null variance was due to normalization to a common factor within each replicate -- thus making the variance zero on purpose. In some cases we will need to repeat this as well (protocol 3, 4, and 5). In other cases (protocol 1 and 2) we used the other variances that were reported as an estimate for the null variances. And where possible (protocol 2) we included additional analysis to allow a direct comparison to the original analysis.

Full details of all power calculations are available through the study's page on the Open Science Framework (<https://osf.io/gnsti/?view_only=f3a48d5a355f429fa2264ee7c17e9705>). Unfortunately, the program we use to calculate sample sizes, G\*Power, only returns whole integers for recommended sample sizes.

*6) For protocol 2, in subsection "Confirmatory analysis plan", a MANOVA is proposed, whereas a one-way ANOVA is suggested for the same protocol in subsection "Test family". Please correct this inconsistency*.

The Confirmatory analysis plan is in reference to the proposed statistical analyses of the replication data. However, as we do not have the raw data needed to perform a power calculation for the MANOVA test, we performed it with a 2-way ANOVA to estimate the needed sample size and adjusted the alpha error for the planned contrasts that will be performed to ensure the sample size is sufficient.

*7) Protocol 5: a mean across several groups is compared with the mean of a single group. This should not be done with a simple* t*-test to take into account the fact that the number of measures is different in the two groups being compared*.

We had originally intended to perform a weighted planned contrast by comparing several groups to a single group -- and agree an F test is properly suited. However, in the revised manuscript we are including multiple independent *t*-tests and one-sample *t*-tests (due to the necessary normalization described in point 5 above) to more thoroughly analyze the data as originally reported and interpreted.

[^1]: Because the original data reported null variances, the calculations below used the average of the non-null variances, 11.9, in place of a SD of 0.

[^2]: With 5 samples per group (30 samples total), power achieved is 99.9%.

[^3]: With a sample size of 5 per group, the achieved power is 95.7%.

[^4]: With a sample size of 5 per group, the achieved power is 99.9%.

[^5]: With a sample size of 5 per group, the achieved power is 99.2%.

[^6]: With a sample size of 5 per group, the achieved power is 99.9%.

[^7]: With a sample size of 5 per group, the achieved power is 99.9%.

[^8]: With 3 samples per group (12 total), achieved power is 99.9%.

[^9]: With 6 samples per group (for a total of 60 samples), the power achieved is 99.9%.

[^10]: With a sample size of 6 per group, the achieved power is 98.9%.

[^11]: With a sample size of 6 per group, the achieved power is 99.5%.

[^12]: With a sample size of 6 per group, the achieved power is 98.8%.

[^13]: With a sample size of 6 per group, the achieved power is 99.9%.

[^14]: With a sample size of 6 per group, the achieved power is 99.1%.

[^15]: With a sample size of 6 per group, the achieved power is 99.9%.

[^16]: With a sample size of 6 per group, the achieved power is 96.9%.

[^17]: With a sample size of 6 per group, the achieved power is 99.9%.

[^18]: With a sample size of 6 per group, the achieved power is 98.7%.

[^19]: With a sample size of 4 per group, the achieved power is 99.9%.

[^20]: With a sample size of 4 per group, the achieved power is 99.9%.

[^21]: With a sample size of 4 per group, the achieved power is 99.9%.

[^22]: Because each replicate will be normalized to TET2 + vehicle this will not have a variance associated with it. And thus the TET2 + vehicle is also not include in the ANOVA calculation.

[^23]: With 12 total samples, the power achieved is 99.9%.

[^24]: With 12 total samples, the power achieved is 99.9%.

[^25]: With 18 total samples, the power achieved is 85.3%.

[^26]: In order to produce quantitative replication data, we will run the experiment six times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.
